Targeting Aberrant Sialylation to Treat Cancer
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cell surface carbohydrates (known as glycans) are often aberrantly expressed or found at atypical levels in cancer. Glycans can impact all steps in tumour progression, from malignant transformation to metastasis, and have roles in all the cancer hallmarks. An increased understanding of glycans in the metastatic cascade offers exciting new therapeutic opportunities. Glycan-based targeting strategies are currently being tested in clinical trials and are a rich and untapped frontier for development. As we learn more about cancer glycobiology, new targets will continue to emerge for drug design. One key change in tumour glycosylation is the upregulation of cancer-associated sialylated glycans. Abnormal sialylation is integral to tumour growth, metastasis and immune evasion; therefore, targeting sialic acid moieties in cancer could be of high therapeutic value. Here, we summarise the changes to sialic acid biology in cancer and discuss recent advances and technologies bringing sialic-acid targeting treatments to the forefront of cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Varki, A. (2017) · Glycobiology · doi:10.1093/glycob/cww086 · Cited by 2,635 · cited 1×
“Glycans are present in many different forms (including glycoproteins, proteoglycans and glycolipids) and build the basis for a universal language (the glycome) that is used for communication between cells [2].”
BackgroundGenes that mediate breast cancer metastasis to the brain
Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., et al. (2009) · Nature · doi:10.1038/nature08021 · Cited by 1,863
Sialic acids sweeten a tumor's life
Büll, C., Stoel, M. A., den Brok, M. H., & Adema, G. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0728 · Cited by 496
The tumour glyco-code as a novel immune checkpoint for immunotherapy
RodrÍguez, E., Schetters, S. T. T., & van Kooyk, Y. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2018.3 · Cited by 473
Sialic acids in cancer biology and immunity
Pearce, O. M. T., & Läubli, H. (2016) · Glycobiology · doi:10.1093/glycob/cwv097 · Cited by 470
Sweet escape: Sialic acids in tumor immune evasion
Büll, C., den Brok, M. H., & Adema, G. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.005 · Cited by 158
Amano, M., Eriksson, H., Manning, J. C., Detjen, K. M., André, S., Nishimura, S., Lehtiö, J., & Gabius, H. (2012) · The FEBS Journal · doi:10.1111/febs.12001 · Cited by 111
Cited by
Emerging phagocytosis checkpoints in cancer immunotherapy
Liu, Y., Wang, Y., Yang, Y., Weng, L., Wu, Q., Zhang, J., Zhao, P., Fang, L., Shi, Y., & Wang, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01365-z · Cited by 275
Foote, C. A., Soares, R. N., Ramirez‐Perez, F. I., Ghiarone, T., Aroor, A., Manrique‐Acevedo, C., Padilla, J., & Martinez‐Lemus, L. (2022) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2022.tb00232.x · Cited by 89
Lee, J.-G., Lee, S., Jeon, J., Kong, H. G., Cho, H.-J., Kim, J.-H., Kim, S.-Y., Oh, M. J., Lee, D., Seo, N., et al. (2022) · Microbiome · doi:10.1186/s40168-021-01191-x · Cited by 26
Metadata
- Authors
- Munkley, J., & Scott, E.
- Venue
- Medicines
- Publisher
- MDPI AG
- Published
- 2019-10-13
- Volume
- 6
- Issue
- 4
- Pages
- 102
- ISSN
- 2305-6320 (ISSN-L)
- OpenAlex
- W2979702819
- Cited by
- 96
- References
- 7
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.